Division of Neonatology and Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA.
J Bone Miner Res. 2011 Oct;26(10):2341-57. doi: 10.1002/jbmr.463.
The need, safety, and effectiveness of vitamin D supplementation during pregnancy remain controversial. In this randomized, controlled trial, women with a singleton pregnancy at 12 to 16 weeks' gestation received 400, 2000, or 4000 IU of vitamin D(3) per day until delivery. The primary outcome was maternal/neonatal circulating 25-hydroxyvitamin D [25(OH)D] concentration at delivery, with secondary outcomes of a 25(OH)D concentration of 80 nmol/L or greater achieved and the 25(OH)D concentration required to achieve maximal 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] production. Of the 494 women enrolled, 350 women continued until delivery: Mean 25(OH)D concentrations by group at delivery and 1 month before delivery were significantly different (p < 0.0001), and the percent who achieved sufficiency was significantly different by group, greatest in 4000-IU group (p < 0.0001). The relative risk (RR) for achieving a concentration of 80 nmol/L or greater within 1 month of delivery was significantly different between the 2000- and the 400-IU groups (RR = 1.52, 95% CI 1.24-1.86), the 4000- and the 400-IU groups (RR = 1.60, 95% CI 1.32-1.95) but not between the 4000- and. 2000-IU groups (RR = 1.06, 95% CI 0.93-1.19). Circulating 25(OH)D had a direct influence on circulating 1,25(OH)(2)D(3) concentrations throughout pregnancy (p < 0.0001), with maximal production of 1,25(OH)(2)D(3) in all strata in the 4000-IU group. There were no differences between groups on any safety measure. Not a single adverse event was attributed to vitamin D supplementation or circulating 25(OH)D levels. It is concluded that vitamin D supplementation of 4000 IU/d for pregnant women is safe and most effective in achieving sufficiency in all women and their neonates regardless of race, whereas the current estimated average requirement is comparatively ineffective at achieving adequate circulating 25(OH)D concentrations, especially in African Americans.
孕期补充维生素 D 的必要性、安全性和有效性仍存在争议。在这项随机对照试验中,12 至 16 孕周的单胎妊娠孕妇每天接受 400、2000 或 4000 IU 的维生素 D3 治疗,直至分娩。主要结局是分娩时产妇/新生儿循环 25-羟维生素 D [25(OH)D] 浓度,次要结局是 25(OH)D 浓度达到 80 nmol/L 或更高,以及达到最大 1,25-二羟维生素 D [1,25(OH)2D] 产量所需的 25(OH)D 浓度。在纳入的 494 名女性中,有 350 名女性继续接受治疗直至分娩:按组分娩时和分娩前 1 个月的平均 25(OH)D 浓度差异有统计学意义(p<0.0001),达到充足水平的比例差异也有统计学意义,4000 IU 组最高(p<0.0001)。2000 IU 组和 400 IU 组(RR=1.52,95%CI 1.24-1.86)、4000 IU 组和 400 IU 组(RR=1.60,95%CI 1.32-1.95)在 1 个月内达到 80 nmol/L 或更高浓度的相对风险(RR)差异有统计学意义,但 4000 IU 组和 2000 IU 组之间(RR=1.06,95%CI 0.93-1.19)无差异。整个孕期循环 25(OH)D 对循环 1,25(OH)2D3 浓度有直接影响(p<0.0001),4000 IU 组所有亚组均能达到最大 1,25(OH)2D3 产量。各组在任何安全性指标上均无差异。没有一个不良事件归因于维生素 D 补充或循环 25(OH)D 水平。研究得出结论,对于孕妇,每天补充 4000 IU 的维生素 D 是安全的,最有效能使所有孕妇及其新生儿达到充足水平,无论种族如何,而目前估计的平均需求量在提高循环 25(OH)D 浓度方面效果较差,尤其是在非裔美国人中。